JP2022509206A5 - - Google Patents
Info
- Publication number
- JP2022509206A5 JP2022509206A5 JP2021529827A JP2021529827A JP2022509206A5 JP 2022509206 A5 JP2022509206 A5 JP 2022509206A5 JP 2021529827 A JP2021529827 A JP 2021529827A JP 2021529827 A JP2021529827 A JP 2021529827A JP 2022509206 A5 JP2022509206 A5 JP 2022509206A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- pharmaceutical composition
- composition according
- pain
- heterocycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862772554P | 2018-11-28 | 2018-11-28 | |
| US62/772,554 | 2018-11-28 | ||
| PCT/US2019/063451 WO2020112905A1 (en) | 2018-11-28 | 2019-11-26 | Methods of treating disease with magl inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022509206A JP2022509206A (ja) | 2022-01-20 |
| JP2022509206A5 true JP2022509206A5 (cg-RX-API-DMAC7.html) | 2022-11-28 |
Family
ID=70851863
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021529827A Pending JP2022509206A (ja) | 2018-11-28 | 2019-11-26 | Magl阻害剤による疾病の治療方法 |
Country Status (15)
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY200738A (en) | 2017-05-23 | 2024-01-13 | H Lundbeck As | Pyrazole magl inhibitors |
| US10927105B1 (en) | 2017-05-23 | 2021-02-23 | Lundbeck La Jolla Research Center, Inc. | Pyrazole MAGL inhibitors |
| KR20230142745A (ko) | 2021-01-29 | 2023-10-11 | 세딜라 테라퓨틱스, 인크. | Cdk2 억제제 및 그의 사용 방법 |
| TW202317560A (zh) | 2021-06-26 | 2023-05-01 | 美商賽迪拉治療股份有限公司 | Cdk2抑制劑及其使用方法 |
| AU2022318349B2 (en) | 2021-07-30 | 2025-12-18 | Confo Therapeutics N.V. | Compounds for the treatment of pain, in particular neuropathic pain, and/or other diseases or disorders that are associated with at2r and/or at2r mediated signaling |
| CA3234430A1 (en) * | 2021-11-02 | 2023-05-11 | Samuel George ANDREW | Crystalline forms of a monoacylglycerol lipase inhibitor |
| IL313987A (en) | 2021-12-29 | 2024-08-01 | Psy Therapeutics Inc | Inhibiting monoacylglycerol lipase (magl) |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2010239188B2 (en) * | 2009-04-22 | 2016-03-31 | Janssen Pharmaceutica Nv | Azetidinyl diamides as monoacylglycerol lipase inhibitors |
| WO2015179559A2 (en) * | 2014-05-21 | 2015-11-26 | Abide Therapeutics, Inc. | Pyrazole compounds and methods of making and using same |
| US10570146B2 (en) * | 2014-07-25 | 2020-02-25 | Northeastern University | Urea/carbamates FAAH MAGL or dual FAAH/MAGL inhibitors and uses thereof |
| WO2017087858A1 (en) * | 2015-11-20 | 2017-05-26 | Abide Therapeutics, Inc. | Pyrazole compounds and methods of making and using same |
| US10519134B2 (en) * | 2015-11-20 | 2019-12-31 | Lundbeck La Jolla Research Center, Inc. | Pyrazole compounds and methods of making and using same |
| KR20170128029A (ko) * | 2016-05-13 | 2017-11-22 | 삼성에스디아이 주식회사 | 태양전지 전극 형성용 조성물 및 이로부터 제조된 전극 |
| JP2020506903A (ja) * | 2017-01-23 | 2020-03-05 | ファイザー・インク | Magl阻害薬としての複素環式スピロ化合物 |
| MY200738A (en) * | 2017-05-23 | 2024-01-13 | H Lundbeck As | Pyrazole magl inhibitors |
| US10927105B1 (en) * | 2017-05-23 | 2021-02-23 | Lundbeck La Jolla Research Center, Inc. | Pyrazole MAGL inhibitors |
-
2019
- 2019-11-26 EP EP19889241.6A patent/EP3886844A4/en not_active Withdrawn
- 2019-11-26 JP JP2021529827A patent/JP2022509206A/ja active Pending
- 2019-11-26 WO PCT/US2019/063451 patent/WO2020112905A1/en not_active Ceased
- 2019-11-26 KR KR1020217019736A patent/KR20210097734A/ko not_active Ceased
- 2019-11-26 MX MX2021006312A patent/MX2021006312A/es unknown
- 2019-11-26 CA CA3120577A patent/CA3120577A1/en active Pending
- 2019-11-26 MA MA054313A patent/MA54313A/fr unknown
- 2019-11-26 BR BR112020015043-6A patent/BR112020015043A2/pt unknown
- 2019-11-26 CN CN201980090281.5A patent/CN113347971A/zh active Pending
- 2019-11-26 US US17/296,489 patent/US20220031676A1/en not_active Abandoned
- 2019-11-26 SG SG11202105320YA patent/SG11202105320YA/en unknown
- 2019-11-26 AU AU2019389017A patent/AU2019389017B2/en not_active Expired - Fee Related
-
2021
- 2021-05-25 CL CL2021001363A patent/CL2021001363A1/es unknown
- 2021-05-27 IL IL283508A patent/IL283508A/en unknown
- 2021-06-09 ZA ZA2021/03975A patent/ZA202103975B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20260098036A1 (en) | 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer | |
| JP6964096B2 (ja) | 3−オキソ−2,6−ジフェニル−2,3−ジヒドロピリダジン−4−カルボキサミド類 | |
| JP2021534124A5 (cg-RX-API-DMAC7.html) | ||
| JP2020521767A5 (cg-RX-API-DMAC7.html) | ||
| US11591311B2 (en) | 3-oxo-6-heteroaryl-2-phenyl-2,3-dihydropyridazine-4-carboxamides | |
| EP3713926B1 (en) | 2-hetarylpyrimidine-4-carboxamides as aryl hydrocarbon receptor anatgonists | |
| AU2018255300A1 (en) | Bicyclic compounds and their use in the treatment of cancer | |
| WO2019101642A1 (en) | Sulphur substituted 3-oxo-2,3-dihydropyridazine-4-carboxamides | |
| US11524944B2 (en) | 2-phenylpyrimidine-4-carboxamides as AHR inhibitors | |
| JP2019512505A5 (cg-RX-API-DMAC7.html) | ||
| CN118843630A (zh) | 作为pkmyt1抑制剂的杂芳族化合物及其用途 | |
| RU2013114771A (ru) | Диамиды азетидинила как ингибиторы моноацилглицерол липазы | |
| RU2015115400A (ru) | Гетероароматические соединения и их применение в качестве допаминовых D1 лигантов | |
| JP2024516033A5 (cg-RX-API-DMAC7.html) | ||
| WO2019090082A1 (en) | Modulators of the integrated stress pathway | |
| WO2018210729A1 (en) | Aromatic sulfonamide derivatives as antagonists or negative allosteric modulators of p2x4 receptor | |
| EA036318B1 (ru) | 6-аминопиридин-3-илтиазолы в качестве модуляторов rort | |
| JP2022530322A5 (cg-RX-API-DMAC7.html) | ||
| JP2015502371A5 (cg-RX-API-DMAC7.html) | ||
| RU2019109570A (ru) | 8-(азетидин-1-ил)-[1,2,4]триазоло[1,5-а]пиридинилы, композиции и способы их применения | |
| JP2024538602A5 (cg-RX-API-DMAC7.html) | ||
| TW201920202A (zh) | 吲哚胺2,3-二氧酶及/或色胺酸2,3-二氧酶的抑制劑 | |
| JP6169699B2 (ja) | 脆弱x症候群、パーキンソン病又は逆流性疾患の治療に有用なジアゼピノン誘導体 | |
| RU2021113744A (ru) | Способы лечения заболевания с использованием ингибиторов magl | |
| NZ790187B2 (en) | C7, C12, and C16 substituted neuroactive steroids and their methods of use |